The first essential step is confirming whether cortisol elevation is pathological and identifying its underlying cause
189 Subsequently, tirzepatide has been extensively investigated in the SURPASS program, a comprehensive development initiative targeting T2DM that is inadequately controlled by various glucose-lowering regimens, including lifestyle alone (SURPASS-1), 190 metformin monotherapy (SURPASS-2), 191 metformin with or without sodium-glucose co-transporter 2 inhibitors (SGLT2i) (SURPASS-3), 192 combination therapy including metformin, SGLT2i, and sulfonylureas (SURPASS-4), 193 insulin glargine with or without metformin (SURPASS-5), 88 and insulin lispro with basal insulin (SURPASS-6)
26(9): 95761 Zhang AQ, Mitchell SC, Smith RL
SeekPeptides remains committed to providing evidence-based peptide education that supports researchers in achieving their optimization goals through systematic, informed approaches